feed
view company updates
tools
perform investment research
network
join events & discussions
advisory
about us
Redeye Capital
Optomed Q3: Go West
Research Note
2021-11-04
17:02
Redeye maintains Optomed's valuation at EUR 13 per share after today's Q3 report and welcomes the orientation to Western markets.
GA
Gergana Almquist
Sign up for free to continue
Sign up with Email
Sign in with Google
Already a member?
Sign in
Disclosures and disclaimers
Premium Plan required to unlock
Unlock companies to access
more high quality research.
View Plans